|
|
Volumn 307, Issue 5707, 2005, Pages 196-198
|
|
Gaps in the safety net
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDEPRESSANT AGENT;
CELECOXIB;
DEXFENFLURAMINE;
NAPROXEN;
ROFECOXIB;
THALIDOMIDE;
ALZHEIMER DISEASE;
ARTHRITIS;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
DRUG MONITORING;
DRUG SAFETY;
DRUG SCREENING;
DRUG TOLERANCE;
EUROPEAN UNION;
FOOD AND DRUG ADMINISTRATION;
HEART INFARCTION;
HUMAN;
NOTE;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
STROKE;
SUICIDE ATTEMPT;
UNITED STATES;
ARTICLE;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG SURVEILLANCE PROGRAM;
ECONOMICS;
EUROPE;
FACTUAL DATABASE;
NEW ZEALAND;
ORGANIZATION AND MANAGEMENT;
PHASE 4 CLINICAL TRIAL;
RISK ASSESSMENT;
ADVERSE DRUG REACTION REPORTING SYSTEMS;
CLINICAL TRIALS;
CLINICAL TRIALS, PHASE IV;
DATABASES, FACTUAL;
DRUG APPROVAL;
DRUG INDUSTRY;
EUROPE;
HUMANS;
NEW ZEALAND;
PRODUCT SURVEILLANCE, POSTMARKETING;
RISK ASSESSMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 13744257166
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.307.5707.196 Document Type: Note |
|
Times cited : (21)
|
|
References (0)
|